Skip to main content
. 2013 Oct 29;109(11):2853–2863. doi: 10.1038/bjc.2013.672

Figure 1.

Figure 1

Expression of miR-125b in glioma samples and C6, U87 and U251 cells. The malignant grade of glioma was evaluated according to WHO criteria as described in Materials and Methods. Samples of ID 1–7 were normal brain tissues from patients with noncancerous disease and were used as the controls; ID 8–16 from pilocytic astrocytomas classified to WHO I; ID 17–26 from astrocytoma classified to WHO II; ID 27–35 from anaplastic astrocytomas classified to WHO III; and ID 36–48 from Glioblastoma Multiforme classified to WHO IV. Each sample was divided by a dashed line. Total RNA was isolated from the glioma tissues and glioma cells of C6, U87 and U251 and real-time PCR was performed to analyse the expression of miR-125b as described in Materials and Methods. The relative expression of miR-125b was expressed as the ratio of the expression level miR-125b to that of U6. *P<0.05 and **P<0.01, as compared with the control group.